China silent heart attack market is estimated to grow considerably at a CAGR of around 7.8% during the forecast period. Increasing heart attacks in China is projected to offer growth to the silent heart attack market in China during the forecast period. According to the World Health Organization (WHO), cardiovascular diseases (CVDs) causes one-third of the total fatalities each year in China. The medical device market is one of the fastest-growing markets in China with double-digit growth for over a decade. In 2018, the medical device market in the country was around $78.8 billion with an increment of 22% YoY. Hospitals are one of the major contributors to the market owing to a 70% market share. As of November 2018, the country has around 32,000 hospitals, out of which more than 12,000 were public hospitals. As per the Institute for Health Metrics and Evaluation (IHME), the incidence of CVD is increasing continuously in the country. Therefore, the presence of such a large number of hospitals with rising CVD patients is offering growth opportunities to the market players to expand their presence in China.
To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/china-silent-heart-attack-market
China silent heart attack market is segmented into diagnosis, treatment, and end-user. Based on the diagnosis, the market is segmented into an electrocardiography (ECG), chest x-ray, computed tomography (CT Scan), echocardiography, and others (blood test). Based on treatment, the market is segmented into medication and surgery. Based on end-user, the market is segmented into hospitals & clinics and ambulatory surgical centers (ASCs). Surgery is one of the most commonly required treatments that increase blood flow. Therefore, angioplasty and bypass surgery are significantly used for the management of blocked arteries and improve blood flow to the heart.
The companies which are contributing to the growth of China silent heart attack market include AstraZeneca PLC, Bayer AG, Siemens AG, F. Hoffmann-La Roche Ltd., Boehringer Ingelheim GmbH, Terumo Corp., and GlaxoSmithKline Plc. The market players are considerably contributing to the market growth by the adoption of various strategies including new product launch, merger, and acquisition, collaborations with government, funding to the start-ups, and technological advancements to stay competitive in the market.
China Silent Heart Attack Market- Segmentation
By Diagnosis
- Electrocardiography (ECG)
- Magnetic Resonance Imaging (MRI)
- Computed Tomography (CT Scan)
- Echocardiography
- Others (Blood Test)
By Treatment
- Medication
- Surgery
- By End-User
- Hospital & Clinics
- Ambulatory Surgical Centers
A full report of China Silent Heart Attack Market is available at: https://www.omrglobal.com/industry-reports/china-silent-heart-attack-market
